Levi & Korsinsky Notifies Fortrea Holdings Inc. (FTRE) Shareholders of Class Action Lawsuit and August 1, 2025 Deadline
https://zlk.com/pslra-1/fortrea-holdings-inc-lawsuit-submission-form?prid=159134&wire=5&utm_campaign=15
or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=sIQSg7_r0dk
THE LAWSUIT: A class action securities lawsuit was filed against Fortrea Holdings Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Fortrea overestimated the amount of revenue the long-term projects in its portfolio, the Pre-Spin Projects, were likely to contribute to the Company's 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the transition services agreements; (iii) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (iv) accordingly, the viability of the Company's post-spin-off business model, as well as its business and/or financial prospects, were overstated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Fortrea Holdings Inc. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/fortrea-holdings-inc-lawsuit-submission-form?prid=159134&wire=5&utm_campaign=15 to learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
15 minutes ago
- Globe and Mail
3 Unstoppable Stocks to Buy in August
Key Points Investors have multiple reasons to like AbbVie stock. Eli Lilly remains a top stock to buy and hold. Vertex Pharmaceuticals is moving quickly to expand its markets beyond cystic fibrosis. 10 stocks we like better than AbbVie › The "it" factor. Some stocks have it. Other stocks don't. But the ones that do can be virtually unstoppable. Three Motley Fool contributors believe they've found such unstoppable stocks with the "it" factor to buy in August -- and they're all in the healthcare sector. Here's why they picked AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). There are many reasons to buy this stock Prosper Junior Bakiny (AbbVie): It's been a little over two years since AbbVie lost patent exclusivity for its best-selling drug, autoimmune disease medicine Humira. That didn't stop AbbVie, though; it just slowed it down momentarily. The company rebounded nicely and has since returned to top-line growth. AbbVie now owns another one of the top-10 selling therapies in the world, Skyrizi, which targets several immunology conditions. Skyrizi's sales have been growing at an incredibly rapid rate. Together with Rinvoq, AbbVie's immunology lineup has successfully filled the gap left by Humira. That's an important reason to consider the stock: AbbVie's ability to overcome a significant patent cliff speaks volumes about its innovative abilities. Beyond that, AbbVie's lineup is deep. It features older products that continue to make meaningful contributions to its financial results, such as its Botox franchise, and newer products that can help drive top-line growth for a while, like migraine treatment Qulipta. AbbVie's pipeline also looks deep. The company should be able to record consistent clinical and regulatory wins. Lastly, we can't mention AbbVie without pointing out its incredible dividend track record. The company is part of the exclusive group of Dividend Kings, boasting an active streak of 53 consecutive payout increases, which includes the time it spent as a division of its former parent company, Abbott Laboratories. AbbVie's forward yield of 3.5% is much higher than the S&P 500 's average of 1.3%, and its cash payout ratio looks reasonable at 61.8%. In addition to an excellent underlying business, a strong lineup, and a solid pipeline, AbbVie is an outstanding stock for income-seeking investors. Investing in this company could yield superior returns over the long term. Eli Lilly is a top growth stock to own for years David Jagielski (Eli Lilly): A stock that looks unstoppable right now is Eli Lilly. While many investors will focus on its highly successful GLP-1 drugs, Zepbound and Mounjaro, as the main reasons to invest in the business, there's much more behind the company, and why it's a top growth stock. Eli Lilly has a promising Alzheimer's treatment, Kisunla, which regulators approved for use last year. It's still in the early innings of its growth and according to analysts, it could generate up to $5 billion in annual revenue at its peak. Meanwhile, Eli Lilly is still focusing on developing more life-changing treatments for patients. It's planning to invest $4.5 billion into a research and manufacturing facility, which it calls Lilly Medicine Foundry. By utilizing new manufacturing methods to ensure high efficiency, the new center can help the company scale and bring new products to market faster. The company also has vast resources at its disposal, which can help it invest in research and development and potentially acquire promising businesses along the way. In the trailing 12 months, Eli Lilly has generated $11.1 billion in profit on sales totaling $49 billion. The company's terrific margins, strong growth prospects, and commitment to producing new treatments are why this pharmaceutical stock can be among the best investments you can put in your portfolio right now. A big biotech innovator that's targeting new markets Keith Speights (Vertex Pharmaceuticals): To truly be unstoppable, a company can't have competition that could, well, stop it. Vertex Pharmaceuticals has this covered with its cystic fibrosis (CF) franchise. No other drugmaker has approved therapies that treat the underlying cause of CF. The number of companies with experimental CF therapies in late-stage clinical testing that could compete with Vertex totals... zero. Actually, Vertex's biggest rival in treating CF is itself. The company's newest CF therapy, Alyftrek, offers a more convenient once-per-day dosing than its current top-seller, Kaftrio/Trikafta. However, CF isn't the main reason why I like Vertex. My primary interests lie with other indications the biotech innovator is targeting. For example, Vertex won U.S. regulatory approval for Journavx earlier this year. It's the first new class of pain medication in over 20 years. Journavx is safe and effective, with none of the side effects and addictive potential associated with opioids -- because it isn't an opioid. The company's pipeline features promising late-stage programs that could further expand Vertex's market opportunity. Inaxaplin targets APOL1-mediated kidney disease, which affects around 250,000 patients worldwide. Povetacicept holds the potential to treat multiple kidney diseases, with IgA nephropathy first on the list with a patient population of over 1 million. Zimislecel could cure severe type 1 diabetes. At first glance, Vertex might seem to be priced at a premium, with its shares trading at 26.3 times forward earnings. However, the company's growth prospects are so strong that its valuation is attractive. Vertex's price-to-earnings-to-growth (PEG) ratio, based on analysts' five-year earnings growth estimates, is a super-low 0.58. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 David Jagielski has no position in any of the stocks mentioned. Keith Speights has positions in AbbVie and Vertex Pharmaceuticals. Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
Globe and Mail
35 minutes ago
- Globe and Mail
Tyler Technologies (TYL) Receives a Rating Update from a Top Analyst
In a report released today, Trevor J. Walsh from Citizens JMP reiterated a Buy rating on Tyler Technologies, with a price target of $700.00. The company's shares closed yesterday at $584.56. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. J. Walsh covers the Technology sector, focusing on stocks such as Zscaler, CyberArk Software, and Cloudflare. According to TipRanks, J. Walsh has an average return of 31.3% and a 73.23% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tyler Technologies with a $672.56 average price target, representing a 15.05% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $708.00 price target. TYL market cap is currently $25.29B and has a P/E ratio of 83.59. Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TYL in relation to earlier this year. Most recently, in June 2025, Brian K. Miller, the EVP & CFO of TYL sold 1,200.00 shares for a total of $696,857.01.
Globe and Mail
35 minutes ago
- Globe and Mail
nVent (NVT) Q2 EPS Up 28 Revenue Up 30
Key Points Adjusted EPS surged 28% to $0.86, topping the $0.79 analyst estimate (non-GAAP) and exceeding expectations by 8.9% on a non-GAAP basis. Revenue (GAAP) climbed 30% to $963 million, beating consensus by 6.0% (GAAP revenue) and reflecting both organic and acquisition-driven growth. Operating margins and free cash flow declined from the prior year, primarily due to acquisition mix and tariff costs. These 10 stocks could mint the next wave of millionaires › nVent Electric Plc (NYSE:NVT), a global provider of electrical connection and protection solutions for infrastructure and industrial markets, published its second quarter 2025 earnings on August 1, 2025. The headline news was a significant beat on both adjusted earnings per share (EPS) (non-GAAP) and revenue (GAAP). Adjusted EPS reached $0.86, up 28% (non-GAAP), outperforming the $0.79 consensus forecast for adjusted EPS (non-GAAP). Reported revenue grew to $963 million (GAAP), outpacing the $908.38 million GAAP estimate and up 30% year-over-year. Most of this growth was driven by large acquisitions in power utilities and data centers, as well as robust product launches. Despite this, both reported and adjusted operating margins (return on sales) and free cash flow (non-GAAP) declined year-over-year. Overall, the quarter demonstrated nVent's ability to deliver on its growth strategy, but also surfaced challenges in margin management and cash flow. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About nVent Electric Plc and Its Strategy nVent Electric Plc designs and manufactures products that connect and protect electrical systems. Its portfolio includes enclosures, electrical connections, and engineered solutions that serve industries such as data centers, utilities, renewables, and industrial automation. The business supports the growing need for safe and reliable power across global infrastructure. The company's current strategy focuses on acquiring businesses that expand its reach in the rapidly growing sectors of electrical infrastructure, data centers, and renewable energy. nVent has made several large acquisitions, including ECM Industries and Trachte, to bolster these offerings. Key to success are continued innovation, reliable supply chain channels, and operational efficiency using lean principles. A strong culture of employee engagement also supports its long-term strategic aims. Quarter Highlights: Financial and Operational Drivers The second quarter featured standout headline growth, with reported revenue up 30%. Organic sales growth, which strips out the effects of acquired businesses and currency, was 9%. Acquisitions contributed 20.7 percentage points to the reported growth, while currency effects were negligible. This growth strategy has intentionally shifted nVent's business mix toward longer-cycle, high-growth infrastructure domains. As a result, power utilities and data centers now make up an estimated 40% of overall company sales. Earnings (non-GAAP) also exceeded expectations. Adjusted EPS climbed to $0.86, an 8.9% beat over consensus and a 28% year-over-year increase. Adjusted operating income also rose by 18%. These gains were supported by strong performances in newly acquired product families like control buildings, bus systems, and switchgear. These are essential systems for managing power distribution and supporting growth in sectors like data centers, power utilities, and renewables. Across product lines, the business launched 35 new offerings in Q1, aiding both organic growth and the company's push into sustainable, electrification-focused markets. While sales momentum was clear, profitability faced pressure. Both operating margin (GAAP) and adjusted return on sales (non-GAAP) dropped from a year earlier -- the adjusted return on sales margin (non-GAAP) fell to 20.8% from 22.9%. This reduction was attributed to margin dilution from acquisitions, additional costs from tariffs, and investments to support second-half growth. The impact was seen across both major segments. Systems Protection's adjusted return on sales reached 21.7%, down 1.8 percentage points, while Electrical Connections adjusted return on sales fell to 28.7%, down 2.2 percentage points year-over-year. Free cash flow (non-GAAP) was $74 million, declining from $100.6 million in Q2 2024. However, the company continued balanced capital allocation, including $253.1 million in share repurchases year-to-date as of Q1 and a dividend of $0.20 per share, which was a 5% increase from the prior year. Business and Product Developments Strategic acquisitions remained central to nVent's expansion this quarter. The integration of Trachte -- a provider of control building systems -- and Avail EPG enhanced nVent's capabilities in high-growth sectors like utilities and data centers. According to management, both acquisitions performed better than expected and contributed to growth synergies. A direct quote from leadership noted: 'The Trachte and Electrical Products Group acquisitions performed better than expected, further strengthening our position in the high growth infrastructure vertical, including power utilities, data centers and renewables.' Product innovation was another highlight. The company introduced 35 new products in the quarter, helping drive double-digit growth in orders and backlog in Q1. Many solutions were designed to meet the growing global demand for electrification, sustainability, and digital transformation. The business emphasized opportunities in data centers, renewables, and electrical grid expansion, with new products tailored for improved energy efficiency and resiliency. These launches complemented nVent's existing portfolio of enclosures and electrical connectors, keeping it aligned with the latest industry trends. The business relies on an extensive distribution network. Over 60% of nVent's revenue now flows through distribution partners, providing broad market access. Management reported strong double-digit order growth, particularly in infrastructure segments for Q1. Growing backlog -- now more than a four-fold increase -- has given the company good visibility for the rest of the year. Operational efficiency is a key part of nVent's culture, with lean manufacturing practices dating back decades. The company called out the doubling of control building output at Trachte as the result of lean improvements. Management also noted that investments and costs related to tariffs weighed on profit margins, but it expects these to be offset over time through pricing, productivity, and integration benefits as new acquisitions are fully absorbed into operations. Looking Ahead: Guidance and Focus Areas nVent raised its full-year 2025 guidance based on strong results and order momentum. Management now expects reported sales growth of 24–26% and organic sales growth of 8–10%. The adjusted EPS (non-GAAP) range was also lifted to $3.22–$3.30, from $3.03–$3.13 previously. For Q3, the business projects reported sales growth of 27–29%, organic growth of 11–13%, and adjusted EPS between $0.86 and $0.88. The company cited its expanded backlog, double-digit order growth, and robust demand in its core infrastructure markets as reasons for its more optimistic full-year outlook. Investors should keep an eye on several areas in the coming quarters. Management has highlighted a $120 million tariff headwind, with plans to offset these costs through pricing, productivity, and supply chain actions. Margin recovery is a top priority, with expectations that synergy capture and pricing actions will improve profitability in the second half of the year. Additionally, trends toward electrification and digital infrastructure are likely to sustain demand for nVent's solutions in years ahead. The quarterly dividend was raised 5% to $0.20 per share, payable in Q3. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,036%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of July 29, 2025
